预约演示

更新于：2025-05-07

OMA1

更新于：2025-05-07

基本信息

别名

FLJ33782、Metalloendopeptidase OMA1, mitochondrial、Metalloprotease-related protein 1

+ [7]

简介

Metalloprotease that is part of the quality control system in the inner membrane of mitochondria (PubMed:20038677, PubMed:25605331, PubMed:32132706, PubMed:32132707). Activated in response to various mitochondrial stress, leading to the proteolytic cleavage of target proteins, such as OPA1, UQCC3 and DELE1 (PubMed:20038677, PubMed:25275009, PubMed:32132706, PubMed:32132707). Involved in the fusion of the mitochondrial inner membranes by mediating cleavage of OPA1 at S1 position, generating the soluble OPA1 (S-OPA1), which cooperates with the membrane form (L-OPA1) to coordinate the fusion of mitochondrial inner membranes (PubMed:31922487). Following stress conditions that induce loss of mitochondrial membrane potential, mediates cleavage of OPA1, leading to excess production of soluble OPA1 (S-OPA1) and negative regulation of mitochondrial fusion (PubMed:20038677, PubMed:25275009). Involved in mitochondrial safeguard in response to transient mitochondrial membrane depolarization (flickering) by catalyzing cleavage of OPA1, leading to excess production of S-OPA1, preventing mitochondrial hyperfusion (By similarity). Also acts as a regulator of apoptosis: upon BAK and BAX aggregation, mediates cleavage of OPA1, leading to the remodeling of mitochondrial cristae and allowing the release of cytochrome c from mitochondrial cristae (PubMed:25275009). In depolarized mitochondria, may also act as a backup protease for PINK1 by mediating PINK1 cleavage and promoting its subsequent degradation by the proteasome (PubMed:30733118). May also cleave UQCC3 in response to mitochondrial depolarization (PubMed:25605331). Also acts as an activator of the integrated stress response (ISR): in response to mitochondrial stress, mediates cleavage of DELE1 to generate the processed form of DELE1 (S-DELE1), which translocates to the cytosol and activates EIF2AK1/HRI to trigger the ISR (PubMed:32132706, PubMed:32132707). Its role in mitochondrial quality control is essential for regulating lipid metabolism as well as to maintain body temperature and energy expenditure under cold-stress conditions (By similarity). Binds cardiolipin, possibly regulating its protein turnover (By similarity). Required for the stability of the respiratory supercomplexes (By similarity).

关联

项与 OMA1 相关的药物

BTM-3566

靶点

OMA1

作用机制

OMA1 agonists

在研机构

Bantam Pharmaceutical LLC

[+1]

原研机构

Bantam Pharmaceutical LLC

在研适应症

难治性成熟B细胞非霍奇金淋巴瘤 [+6]

非在研适应症-

最高研发阶段临床1期

首次获批国家/地区-

首次获批日期1800-01-20

BTM-3528

靶点

OMA1

作用机制

OMA1调节剂

在研机构

Bantam Pharmaceutical LLC

原研机构

Bantam Pharmaceutical LLC

在研适应症

弥漫性大B细胞淋巴瘤

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期1800-01-20

项与 OMA1 相关的临床试验

NCT06792734

/ Recruiting临床1期

Phase 1A/1B Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas

The goal of this clinical trial is to learn if BMT-3566 can safety be given to adult patients with relapsed or refractory mature b cell lymphomas. It will also learn how well BTM-3566 works to treat relapsed or refractory mature b cell lymphomas. The main questions it aims to answer are:
What are the side effects of BTM-3566 at different doses? What are the levels of BTM-3566 in the blood at different timepoints around dosing? What is the clinical benefit of BTM-3566 in treating cancer (i.e. how well does it slow or stop disease progression)?
Participants will:
Take BTM-3566 in 14-day periods with 7 days of dosing followed by 7 days of no dosing Visit the clinic regularly for checkups and tests Keep a diary of their dosing and weight

开始日期2025-02-01

申办/合作机构

Bantam Pharmaceutical LLC

100 项与 OMA1 相关的临床结果

登录后查看更多信息

100 项与 OMA1 相关的转化医学

登录后查看更多信息

0 项与 OMA1 相关的专利（医药）

登录后查看更多信息

192

项与 OMA1 相关的文献（医药）

2025-05-01·Journal of Biological Chemistry

H2S remodels mitochondrial ultrastructure and destabilizes respiratory supercomplexes

Article

作者: Hanna, David A ; Shah, Yatrik M ; Khalimonchuk, Oleh ; Chen, Brandon ; Banerjee, Ruma ; Cunniff, Brian

Mitochondrial form and function are intimately interconnected, responding to cellular stresses and changes in energy demand. Hydrogen sulfide, a product of amino acid metabolism, has dual roles as an electron transport chain substrate and complex IV (CIV) inhibitor, leading to a reductive shift, which has pleiotropic metabolic consequences. Luminal sulfide concentration in the colon is high due to microbial activity, and in this study, we demonstrate that chronic sulfide exposure of colonocyte-derived cells leads to lower Mic60 and Mic19 expression that is correlated with a profound loss of cristae and lower mitochondrial networking. Sulfide-induced depolarization of the inner mitochondrial membrane activates Oma1-dependent cleavage of Opa1 and is associated with a profound loss of CI and CIV activities associated with respirasomes. Our study reveals a potential role for sulfide as an endogenous modulator of mitochondrial dynamics and suggests that this regulation is corrupted in hereditary or acquired diseases associated with elevated sulfide.

2025-04-01·Cytotechnology

Mechanism underlying the role of the circRNA OMA1/miR-654-3p/RAF1 axis in children with inflammatory bowel disease

Article

作者: Xu, Yufen ; Wang, Zhenhui ; Wu, Meirong ; Zhang, Ping

Inflammatory bowel disease (IBD), a chronic gastrointestinal disorder, often emerges during childhood and poses significant challenges due to its adverse effects on growth, development, and psychosocial well-being. Circular RNAs (circRNAs) have been implicated in the pathogenesis of diverse diseases. However, the specific biological role and mechanisms of circRNA OMA1 in children with IBD remain largely unexplored. This study investigates the functions and mechanistic pathways of circRNA OMA1 in the progression of IBD. Quantitative real-time PCR (qRT-PCR) was employed to quantify circRNA OMA1 and miR-654-3p expression levels in the serum of children with IBD and in HT-29 cells. Downstream miRNA and mRNA targets of circRNA OMA1 were predicted using StarBase and validated via luciferase reporter assays. An in vitro IBD model was established by treating the human colonic epithelial cell line (HT-29) with 2% dextran sulfate sodium (DSS). Cell viability and apoptosis were assessed using the MTT assay and flow cytometry, respectively. Expression of the apoptosis-related protein cleaved caspase-3 was analyzed via western blotting, and proinflammatory cytokine levels (TNF-α, IL-1β, and IL-6) were measured using ELISA. The expression of circRNA OMA1 was notably lower in the serum of children with IBD and in DSS-treated HT-29 cells than in healthy controls, whereas miR-654-3p expression was upregulated. Bioinformatics analyses revealed a direct interaction between circRNA OMA1 and miR-654-3p. Overexpression of circRNA OMA1 through plasmid transfection increased circRNA OMA1 levels and suppressed miR-654-3p expression in HT-29 cells under both basal and DSS-stimulated conditions. Conversely, transfection with a miR-654-3p mimic reversed these effects. Upregulation of circRNA OMA1 ameliorated DSS-induced injury in HT-29 cells by enhancing cell viability, reducing apoptosis, and downregulating cleaved caspase-3 expression. Moreover, circRNA OMA1 overexpression inhibited the secretion of inflammatory cytokines TNF-α, IL-1β, and IL-6. However, these protective effects were partially reversed by treatment with the miR-654-3p mimic. Additionally, miR-654-3p was shown to directly target RAF1, negatively regulating its expression. The proliferation-promoting and apoptosis-suppressing effects of miR-654-3p inhibitor treatment were mitigated by RAF1-siRNA. Conclusion: Upregulation of circRNA OMA1 alleviates DSS-induced colonic cell apoptosis and inflammation by modulating the miR-654-3p/RAF1 axis. These findings suggest that circRNA OMA1 could be a promising biomarker for the diagnosis and treatment of IBD.Supplementary InformationThe online version contains supplementary material available at 10.1007/s10616-025-00703-z.

2025-03-20·Nature

Dual regulation of mitochondrial fusion by Parkin–PINK1 and OMA1

Article

作者: Quirós, Pedro M ; Yamada, Tatsuya ; Langer, Thomas ; Dawson, Valina L ; Sesaki, Hiromi ; Murata, Daisuke ; Adachi, Yoshihiro ; López-Otín, Carlos ; Khare, Pratik ; Blackshaw, Seth ; Le, Anne ; Iijima, Miho ; Ito, Fumiya ; Ikeda, Arisa ; Dawson, Ted M ; Zhang, Cissy ; Wang, Hu ; Chan, David C

Mitochondrial stress pathways protect mitochondrial health from cellular insults^1-8. However, their role under physiological conditions is largely unknown. Here, using 18 single, double and triple whole-body and tissue-specific knockout and mutant mice, along with systematic mitochondrial morphology analysis, untargeted metabolomics and RNA sequencing, we discovered that the synergy between two stress-responsive systems-the ubiquitin E3 ligase Parkin and the metalloprotease OMA1-safeguards mitochondrial structure and genome by mitochondrial fusion, mediated by the outer membrane GTPase MFN1 and the inner membrane GTPase OPA1. Whereas the individual loss of Parkin or OMA1 does not affect mitochondrial integrity, their combined loss results in small body size, low locomotor activity, premature death, mitochondrial abnormalities and innate immune responses. Thus, our data show that Parkin and OMA1 maintain a dual regulatory mechanism that controls mitochondrial fusion at the two membranes, even in the absence of extrinsic stress.

项与 OMA1 相关的新闻（医药）

2025-04-25

·PRNewswire

Bantam Pharmaceutical Presents New Preclinical Data for BTM-3566 at the American Association for Cancer Research (AACR) Annual Meeting 2025

• BTM-3566 shows solid tumor regression and identifies FAM210B as a potential biomarker for response and combination strategies RESEARCH TRIANGLE PARK, N.C., April 25, 2025 /PRNewswire/ -- Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, today announced solid tumor regression data from Bantam's lead product candidate, BTM-3566. These preclinical data will be shared in a poster presentation during the American Association for Cancer Research (AACR) Annual Meeting, being held from April 25-30, 2025 at the McCormick Place Convention Center in Chicago, Illinois. The poster highlights evidence of robust anti-tumor activity in a broad range of solid tumor models, as well as introduces FAM210B, a mitochondrial protein, as a potential biomarker for response. BTM-3566 is a first-in-class, small molecule cancer therapeutic which targets difficult-to-treat, aggressive tumors by activating OMA1-ATF4 Integrated Stress Response (ISR), a newly described mitochondrial homeostasis pathway. Previously, BTM-3566 was shown to have strong single-agent activity in both cell line and patient-derived xenograft (PDX) models of mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL), regardless of cell of origin (COO) or genotype. The new data extend these findings to solid tumors and demonstrate that BTM-3566 has in vitro and in vivo activity across tumor types. Key findings include: BTM-3566 exhibits in vitro and in vivo activity in a broad range of solid tumor models BTM-3566 drives tumor regression in models with low FAM210B RNA expression, supporting the use of FAM210B as a potential biomarker for response Ectopic expression of FAM210B blocks drug activity in multiple models, suggesting a mechanistic role for the protein in mediating response BTM-3566 demonstrates additive and synergistic activity in combination with other agents from multiple classes in preclinical models, including BH3 mimetics, supporting future combination strategies "These findings provide important insight into the unique mechanism of our lead compound and support the potential for future patient selection using FAM210B expression," said Michael Stocum, President & CEO of Bantam Pharmaceutical. "We believe BTM-3566 holds promise not only as a monotherapy but also in combination with numerous approved anti-cancer agents, potentially expanding treatment options for patients with aggressive, hard-to-treat tumors. We intend to further explore these relationships as product development progresses." Poster Presentation Details Title: Selective pharmacological activation of the mitochondrial protease OMA1 inhibits tumor growth and induces regression in tumors expressing low levels of FAM210B Presenter: Matthew Kostura, PhD, Chief Scientific Officer, Bantam Pharmaceutical Session: Experimental and Molecular Therapeutics Date/Time: Monday, April 28th at 3 p.m. to 6 p.m. ET Abstract Number: 3032 The poster presentation will be available under the News & Resources section of the company's website shortly after the event. About BTM-3566 BTM-3566 is a novel, orally available small molecule designed to target a wide range of cancers, including both hematologic and solid tumors. Its initial clinical focus is on mature B-cell lymphomas, such as mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL). In preclinical studies, BTM-3566 demonstrated potent anti-cancer activity, driving significant tumor regression – and in many cases, complete tumor elimination – in models resistant to standard treatments, including CAR-T cell therapy. BTM-3566 works by disrupting the mitochondrial function in tumor cells, triggering their natural cell death process (apoptosis). With its unique mechanism of action and strong preclinical data, Bantam also plans to expand clinical development into solid tumors, broadening its potential impact for patients with limited treatment options. Currently, Bantam is conducting an ongoing Phase 1 clinical trial in both the U.S. and Canada evaluating BTM-3566 in relapsed/refractory mature B-cell lymphomas. For more information about the U.S. trial, visit ClinicalTrials.gov and search NCT06792734. About Bantam Pharmaceutical Bantam Pharmaceutical is a drug discovery and development company leveraging the power of mitochondrial dynamics to address critical unmet needs in oncology. Using its unique expertise in mitochondrial cellular biology, Bantam is advancing novel, first-in-class oral small molecule therapeutics for difficult-to-treat hematological and solid tumors. The company currently holds an active Investigational New Drug (IND) application in the U.S. and a Clinical Trial Application (CTA) in Canada for its lead candidate, BTM-3566, targeting B-cell malignancies, with plans to expand clinical development into solid tumors. Learn more at . Media Contact Jennifer Almond Corporate Communications Bantam Pharmaceutical [email protected] SOURCE Bantam Pharmaceutical, LLC WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床1期临床申请细胞疗法AACR会议免疫疗法

2025-03-06

·PRNewswire

Bantam Pharmaceutical Accelerates BTM-3566 Clinical Program Expanding Phase 1 Trial into Canada

RESEARCH TRIANGLE PARK, N.C., March 6, 2025 /PRNewswire/ -- Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, today announced it is proceeding with a Phase 1 clinical trial evaluating BTM-3566 in relapsed/refractory mature B-cell lymphomas, based on a recent Clinical Trial Application (CTA) cleared by Health Canada. This regulatory milestone enables Bantam to expand its ongoing clinical program and to activate multiple clinical trial sites in Canada early in the second quarter of 2025. This clearance follows the recent activation of Bantam's first U.S. clinical trial site at The University of Texas MD Anderson Cancer Center for its BTM-3566 Phase 1 study. BTM-3566 is a first-in-class, small molecule cancer therapeutic which targets mitochondrial homeostasis via the ATF4-Integrated Stress Response (ISR) pathway to treat aggressive tumors. "Activating clinical sites in Canada alongside our U.S. study sites is a key step in building a high-quality, efficient, and thoughtful clinical program," said Michael Stocum, President & CEO of Bantam Pharmaceutical. "This complementary approach accelerates the identification of clinically active doses for lymphoma patients while maintaining the scientific rigor needed to ensure a meaningful impact for those in need. We anticipate this expansion to enable us to achieve our clinical objectives sooner than originally projected." The Phase 1 trial is designed to evaluate the safety, tolerability, and preliminary efficacy of BTM-3566 in patients with relapsed/refractory mature B-cell lymphomas. The Canadian trial will follow a similar overall design to the ongoing U.S. Phase 1 trial, a multicenter, open-label, and dose-escalation study assessing the safety, tolerability, pharmacokinetics, anti-tumor activity, and pharmacodynamic effects of BTM-3566. The dual country strategy was implemented to accelerate the development of BTM-3566 and will support future harmonization between the studies to generate a robust dataset and inform future development. Initial clinical data from the trial are expected in the second half of 2025. For more information about the ongoing clinical trial, visit ClinicalTrials.gov and search NCT number NCT06792734. About BTM-3566 BTM-3566 is a novel, orally available small molecule designed to target a wide range of cancers, including both hematologic and solid tumors. Its initial clinical focus is on mature B-cell lymphomas, such as mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL). In preclinical studies, BTM-3566 demonstrated potent anti-cancer activity, driving significant tumor regression – and in many cases, complete tumor elimination – in models resistant to standard treatments, including CAR-T cell therapy. BTM-3566 works by disrupting the mitochondrial function in tumor cells, triggering their natural cell death process (apoptosis). With its unique mechanism of action and strong preclinical data, Bantam also plans to expand clinical development into solid tumors, broadening its potential impact for patients with limited treatment options. About Bantam Pharmaceutical Bantam Pharmaceutical is a drug discovery and development company leveraging the power of mitochondrial dynamics to address critical unmet needs in oncology. Using its unique expertise in mitochondrial cellular biology, Bantam is advancing novel, first-in-class oral small molecule therapeutics for difficult-to-treat hematological and solid tumors. The company currently holds an active Investigational New Drug (IND) application in the U.S. and a Clinical Trial Application (CTA) in Canada for its lead candidate, BTM-3566, targeting B-cell malignancies, with plans to expand clinical development into solid tumors. Learn more at . Media Contact Jennifer Almond Corporate Communications Bantam Pharmaceutical [email protected] SOURCE Bantam Pharmaceutical, LLC WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床申请临床1期细胞疗法免疫疗法

2025-03-05

·药事纵横

重大突破！2月这些首次进入临床的靶点，开启医药新征程

在新药研发的漫漫征途中，药物首次进入临床试验，无疑是一个极具意义的重大里程碑。这背后意味着相关靶点已完成了基因表达、蛋白质结构和功能等多方面的生物学功能验证，极有可能在对应疾病的发病机制里扮演着关键角色，为攻克疾病带来新的希望。今天，就让我们一同深入了解几个在2月崭露头角、首次进入临床的重要靶点。 OMA1：线粒体健康的“守护者”与疾病治疗新靶点 OMA1是位于线粒体内膜的锌金属蛋白酶，由OMA1基因编码。它在维持线粒体动态平衡和应激响应方面发挥着核心作用。当细胞遭遇应激，如膜电位丧失或线粒体损伤时，OMA1就会被激活，它会切割线粒体融合蛋白OPA1的长亚型，抑制线粒体融合并促进裂变。不仅如此，OMA1还能降解DELE1和PINK1等蛋白，通过调控线粒体自噬和细胞凋亡，影响细胞的最终命运。比如在细胞凋亡过程中，Bax/Bak蛋白聚集激活OMA1，引发一系列反应，最终触发凋亡。 OMA1的表达与多种疾病紧密相关。在骨肉瘤中，OMA1高表达与肿瘤发生和肺转移有关，敲除它能抑制肿瘤生长；但在肺腺癌里，OMA1低表达却通过抑制PI3K/AKT通路，减少癌细胞增殖。此外，OMA1缺失的小鼠会出现肥胖、代谢异常和线粒体功能障碍，这表明它在代谢疾病方面也有着潜在的影响。目前，抗真菌药物环吡罗可诱导OMA1自裂解，抑制肿瘤发展；而某些激酶抑制剂却可能因激活OMA1引发心脏毒性。由此可见，OMA1不仅是线粒体质量控制的关键调节因子，更是多种疾病治疗的潜在重要靶点。 BTM-3566：基于OMA1靶点的抗癌新星 BTM-3566是Bantampharma开发的OMA1小分子激动剂，它的出现为癌症治疗带来了新的曙光。BTM-3566能够诱导OMA1激活，进而使线粒体蛋白OPA1和DELE1裂解，激活HRI激酶，磷酸化eIF2a。eIF2a则调节综合应激反应(ISR)，根据细胞环境触发稳态适应或细胞凋亡，以此来对抗癌细胞。 BTM-3566的研究进展备受关注。它在2021年ASH会议上初次亮相，目前正在开展1期临床试验（NCT06792734），用于治疗复发/难治性成熟B细胞淋巴瘤，预计2026年初公布临床试验结果。在抗癌效果上，BTM-3566表现十分亮眼。对具有高风险基因组改变（如Myd88突变和MYC、BCL2重排）的人类DLBCL PDX模型研究发现，100%的细胞系都有反应，8个PDX模型中有6个肿瘤完全消退。在套细胞淋巴瘤方面，BTM-3566能抑制细胞增殖并诱导凋亡，且不受伊布替尼和维奈克拉耐药状态的影响。在不同的动物模型中，BTM-3566也展现出强大的实力，在CDX和多种耐药的PDX小鼠模型中，几乎能完全抑制肿瘤生长。而且，BTM-3566不局限于血液瘤，在实体瘤如绒毛膜癌和食管癌中也有一定的肿瘤抑制效果，尽管效果不如血液瘤，但已经为实体瘤治疗提供了新的思路。从商业化角度来看，弥漫性大B细胞淋巴瘤市场前景广阔。2023年，该市场规模达到39亿美元，预计到2034年将增长至52亿美元，2024 - 2034年期间的增长率 (CAGR) 为2.7%。套细胞淋巴瘤作为非霍奇金淋巴瘤的亚类，占比6％ - 8％。全球套细胞淋巴瘤治疗市场预计2024年达到25.3亿美元，并在2024 - 2034年以8.6%的复合年增长率扩大。目前，在OMA1靶点的药物研发领域，Bantampharma处于领先地位，其研发的BTM-3566和BTM-3528为众多患者带来了新的希望。 CAPN2：隐藏在细胞深处的“多面手”靶点 CAPN2属于钙蛋白酶家族，是一种钙依赖性、非溶酶体半胱氨酸蛋白酶。它在细胞中身兼数职，是细胞骨架重塑与信号转导的“调节者”，通过有限蛋白水解作用，分解关键底物，调节细胞的结构和功能。在神经元领域，CAPN2参与神经元刺激诱导的CPEB3蛋白水解裂解，影响CPEB3靶标mRNA的翻译，与轴突退化密切相关。此外，它在肿瘤发生与转移过程中也扮演着重要角色，比如在胰腺癌中，CAPN2上调可通过Wnt/β-Catenin信号通路调节上皮间质转化，促进肿瘤细胞的增殖、迁移和侵袭。 AMX-0114：靶向CAPN2，为神经疾病带来希望 AMX0114是Amylyx开发的靶向CAPN2的反义寡核苷酸。它能靶向CAPN2蛋白酶活性位点中的一个外显子，通过RNase H介导的降解降低CAPN2 mRNA转录本的水平，从而减少细胞中功能性钙蛋白酶2蛋白的含量。目前，AMX0114正在加拿大进行ALS（肌萎缩侧索硬化症）的1期临床试验（NCT06665165）。在多项研究中，AMX0114展现出了良好的治疗潜力。在诱导多能干细胞衍生的运动神经元模型中，预处理AMX0114后，再暴露于神经毒性化合物，结果显示它能显著降低细胞外神经丝轻链（NfL）水平，而NfL是中枢神经系统疾病中轴突损伤的生物标志物，这意味着AMX0114在减轻神经损伤方面效果显著。在携带ALS相关TDP-43(M337V)突变的诱导多能干细胞衍生神经元模型中，AMX0114不仅改善了神经元的生存率，还降低了细胞外NfL水平。在氧化应激诱导的神经细胞死亡模型中，AMX0114预处理的神经元在过氧化氢暴露下，细胞体面积保留率远高于对照组，显著抑制了CAPN2的活性，实现了有效的神经保护。在商业价值方面，目前获批的ALS新药托夫生（Tofersen，QALSODY）已取得一定的销售成绩，2024年全球销售额达3200万美元。专业人士预计AMX0114峰值年销售额可达1.5亿美元。2023年，全球ALS治疗市场规模为6.673亿美元，预计2024 - 2030年将以5.8%的复合年增长率增长，其中药物治疗占比63.1%，干细胞治疗也在快速发展。目前针对CAPN2靶点的在研药物仅6款，竞争相对不激烈，这也为AMX0114的发展提供了广阔空间。结语这些首次进入临床的靶点，无论是OMA1、CAPN2，还是基于它们开发的BTM-3566、AMX0114，都在各自的领域展现出了巨大的潜力。它们不仅为相关疾病的治疗带来了新的方向，也为医药市场注入了新的活力。让我们共同期待这些靶点和药物在未来能取得更多的突破，为患者带来更多的希望！参考资料 1.Shammas MK, Huang X, Wu BP, et al. OMA1 mediates local and global stress responses against protein misfolding in CHCHD10 mitochondrial myopathy. J Clin Invest. 2022;132(14):e157504. doi:10.1172/JCI157504 2.Bantampharma website 3.Coherent Market Insight 4.Grand View Research 5.Amylyx Website 药事纵横投稿须知：稿费已上调，欢迎投稿

临床1期临床结果临床终止